Physician profile
Gerry Situ
NPI 1285227272
$1,121.62
in general payments reported to CMS, 2019-2025
18 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $72.31 · 2023: $240 · 2024: $423 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $124.64 | 2023-2024 | Yupelri |
| Pfizer INC. | $117.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.70 | 2023-2025 | Breztri, Farxiga |
| Abbvie INC. | $104.30 | 2023-2025 | |
| Astellas Pharma US INC | $102.98 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $94.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $93.10 | 2022-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $78.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Viatris Specialty LLC | $61.30 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.54 | 2023-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $48.82 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $23.89 | 2025 | Rexulti |
| Coopersurgical, INC. | $22.84 | 2025 | Paragard T 380a |
| Janssen Pharmaceuticals, INC | $20.55 | 2023 | Xarelto |
| Angiodynamics, INC. | $18.01 | 2024 | Auryon Laser System 100-120 Vac |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.27 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $15.52 | 2024 | Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $14.69 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerry Situ listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.